201 related articles for article (PubMed ID: 18338208)
1. Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease.
Tominaga Y; Tsuzuki T; Matsuoka S; Uno N; Sato T; Shimabukuro S; Goto N; Nagasaka T; Uchida K
World J Surg; 2008 May; 32(5):815-21. PubMed ID: 18338208
[TBL] [Abstract][Full Text] [Related]
2. Parafibromin expression, single-gland involvement, and limited parathyroidectomy in familial isolated hyperparathyroidism.
Iacobone M; Barzon L; Porzionato A; Masi G; Macchi V; Marino F; Viel G; Favia G
Surgery; 2007 Dec; 142(6):984-91; discussion 984-91. PubMed ID: 18063086
[TBL] [Abstract][Full Text] [Related]
3. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
Gill AJ; Clarkson A; Gimm O; Keil J; Dralle H; Howell VM; Marsh DJ
Am J Surg Pathol; 2006 Sep; 30(9):1140-9. PubMed ID: 16931959
[TBL] [Abstract][Full Text] [Related]
4. Loss of parafibromin expression in a subset of parathyroid adenomas.
Juhlin C; Larsson C; Yakoleva T; Leibiger I; Leibiger B; Alimov A; Weber G; Höög A; Villablanca A
Endocr Relat Cancer; 2006 Jun; 13(2):509-23. PubMed ID: 16728578
[TBL] [Abstract][Full Text] [Related]
5. Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features.
Gill AJ; Lim G; Cheung VKY; Andrici J; Perry-Keene JL; Paik J; Sioson L; Clarkson A; Sheen A; Luxford C; Elston MS; Meyer-Rochow GY; Nano MT; Kruijff S; Engelsman AF; Sywak M; Sidhu SB; Delbridge LW; Robinson BG; Marsh DJ; Toon CW; Chou A; Clifton-Bligh RJ
Am J Surg Pathol; 2019 Jan; 43(1):35-46. PubMed ID: 29324469
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
Howell VM; Gill A; Clarkson A; Nelson AE; Dunne R; Delbridge LW; Robinson BG; Teh BT; Gimm O; Marsh DJ
J Clin Endocrinol Metab; 2009 Feb; 94(2):434-41. PubMed ID: 19017757
[TBL] [Abstract][Full Text] [Related]
7. CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.
Hahn MA; Howell VM; Gill AJ; Clarkson A; Weaire-Buchanan G; Robinson BG; Delbridge L; Gimm O; Schmitt WD; Teh BT; Marsh DJ
Endocr Relat Cancer; 2010 Mar; 17(1):273-82. PubMed ID: 20026646
[TBL] [Abstract][Full Text] [Related]
8. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
Cetani F; Ambrogini E; Viacava P; Pardi E; Fanelli G; Naccarato AG; Borsari S; Lemmi M; Berti P; Miccoli P; Pinchera A; Marcocci C
Eur J Endocrinol; 2007 May; 156(5):547-54. PubMed ID: 17468190
[TBL] [Abstract][Full Text] [Related]
9. Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.
Cetani F; Pardi E; Ambrogini E; Banti C; Viacava P; Borsari S; Bilezikian JP; Pinchera A; Marcocci C
J Endocrinol Invest; 2008 Oct; 31(10):900-4. PubMed ID: 19092296
[TBL] [Abstract][Full Text] [Related]
10. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma.
Kim HK; Oh YL; Kim SH; Lee DY; Kang HC; Lee JI; Jang HW; Hur KY; Kim JH; Min YK; Chung JH; Kim SW
Head Neck; 2012 Feb; 34(2):201-6. PubMed ID: 21717519
[TBL] [Abstract][Full Text] [Related]
11. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma.
Shattuck TM; Välimäki S; Obara T; Gaz RD; Clark OH; Shoback D; Wierman ME; Tojo K; Robbins CM; Carpten JD; Farnebo LO; Larsson C; Arnold A
N Engl J Med; 2003 Oct; 349(18):1722-9. PubMed ID: 14585940
[TBL] [Abstract][Full Text] [Related]
12. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.
Juhlin CC; Haglund F; Obara T; Arnold A; Larsson C; Höög A
Virchows Arch; 2011 Jul; 459(1):47-53. PubMed ID: 21221636
[TBL] [Abstract][Full Text] [Related]
13. Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours.
Bradley KJ; Cavaco BM; Bowl MR; Harding B; Cranston T; Fratter C; Besser GM; Conceição Pereira M; Davie MW; Dudley N; Leite V; Sadler GP; Seller A; Thakker RV
Clin Endocrinol (Oxf); 2006 Mar; 64(3):299-306. PubMed ID: 16487440
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.
Witteveen JE; Hamdy NA; Dekkers OM; Kievit J; van Wezel T; Teh BT; Romijn JA; Morreau H
Mod Pathol; 2011 May; 24(5):688-97. PubMed ID: 21240254
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid cancer.
Sharretts JM; Kebebew E; Simonds WF
Semin Oncol; 2010 Dec; 37(6):580-90. PubMed ID: 21167377
[TBL] [Abstract][Full Text] [Related]
16. Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism.
Bricaire L; Odou MF; Cardot-Bauters C; Delemer B; North MO; Salenave S; Vezzosi D; Kuhn JM; Murat A; Caron P; Sadoul JL; Silve C; Chanson P; Barlier A; Clauser E; Porchet N; Groussin L;
J Clin Endocrinol Metab; 2013 Feb; 98(2):E403-8. PubMed ID: 23293331
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic Profiling and Molecular Mechanisms in Hyperparathyroidism-jaw Tumor Syndrome.
Tora R; Welch J; Sun J; Agarwal SK; Bell DA; Merino M; Weinstein LS; Simonds WF; Jha S
J Clin Endocrinol Metab; 2023 Nov; 108(12):3165-3177. PubMed ID: 37339334
[TBL] [Abstract][Full Text] [Related]
18. Hyperparathyroidism-jaw tumor syndrome: Results of operative management.
Mehta A; Patel D; Rosenberg A; Boufraqech M; Ellis RJ; Nilubol N; Quezado MM; Marx SJ; Simonds WF; Kebebew E
Surgery; 2014 Dec; 156(6):1315-24; discussion 1324-5. PubMed ID: 25444225
[TBL] [Abstract][Full Text] [Related]
19. Understanding the genetic basis of parathyroid carcinoma.
Gill AJ
Endocr Pathol; 2014 Mar; 25(1):30-4. PubMed ID: 24402736
[TBL] [Abstract][Full Text] [Related]
20. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma.
Tan MH; Morrison C; Wang P; Yang X; Haven CJ; Zhang C; Zhao P; Tretiakova MS; Korpi-Hyovalti E; Burgess JR; Soo KC; Cheah WK; Cao B; Resau J; Morreau H; Teh BT
Clin Cancer Res; 2004 Oct; 10(19):6629-37. PubMed ID: 15475453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
